TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:08
Biodexa Pharmaceuticals Plc ( BDRX )
4.70USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-92.85%
BDRX
SPY
32.66%
-99.99%
BDRX
SPY
108.59%
-100.00%
BDRX
SPY
302.52%
BDRX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.41
-3.65
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.20
3.09
0.16
-113.62
0.00
0.44
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-4170.09
-2161.57
-4102.94
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.6192
-156.64
-157.95
1.44
Other Earnings and Cash Flow Stats:
Biodexa Pharmaceuticals Plc ( BDRX ) Net Income TTM ($MM) is -7.21
Biodexa Pharmaceuticals Plc ( BDRX ) Operating Income TTM ($MM) is -7.70
Biodexa Pharmaceuticals Plc ( BDRX ) Owners' Earnings Annual ($MM) is 0.00
Biodexa Pharmaceuticals Plc ( BDRX ) Current Price to Owners' Earnings ratio is 0.00
Biodexa Pharmaceuticals Plc ( BDRX ) EBITDA TTM ($MM) is -7.55
Biodexa Pharmaceuticals Plc ( BDRX ) EBITDA Margin is -4102.94%
Capital Allocation:
Biodexa Pharmaceuticals Plc ( BDRX ) has paid 0.00 dividends per share and bought back 1.00319 million shares in the past 12 months
Biodexa Pharmaceuticals Plc ( BDRX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Biodexa Pharmaceuticals Plc ( BDRX ) Interest-bearing Debt ($MM) as of last quarter is 0
Biodexa Pharmaceuticals Plc ( BDRX ) Annual Working Capital Investments ($MM) are -2
Biodexa Pharmaceuticals Plc ( BDRX ) Book Value ($MM) as of last quarter is 8
Biodexa Pharmaceuticals Plc ( BDRX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Biodexa Pharmaceuticals Plc ( BDRX ) has 5 million in cash on hand as of last quarter
Biodexa Pharmaceuticals Plc ( BDRX ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Biodexa Pharmaceuticals Plc ( BDRX ) has 0 common shares outstanding as of last quarter
Biodexa Pharmaceuticals Plc ( BDRX ) has 0 million USD of preferred stock value
Academic Scores:
Biodexa Pharmaceuticals Plc ( BDRX ) Altman Z-Score is -16.29 as of last quarter
Biodexa Pharmaceuticals Plc ( BDRX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Biodexa Pharmaceuticals Plc ( BDRX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Biodexa Pharmaceuticals Plc ( BDRX ) for the amount of $ on
10.16% of Biodexa Pharmaceuticals Plc ( BDRX ) is held by insiders, and 35.25% is held by institutions
Biodexa Pharmaceuticals Plc ( BDRX ) went public on 2015-12-07
Other Biodexa Pharmaceuticals Plc ( BDRX ) financial metrics:
FCF:-8.11
Unlevered Free Cash Flow:0.00
EPS:-0.81
Operating Margin:-4170.09
Gross Profit Margin:-2161.57
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-75.81
Beta:1.44
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Biodexa Pharmaceuticals Plc ( BDRX ) :
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.